MedTrace Logo

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

NCT00234468 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2011-05-20

No results posted yet for this study

Summary

The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy

Conditions

  • Non Small Cell Lung Carcinoma

Interventions

DRUG

Iressa (Gefitinib)

Sponsors & Collaborators

Principal Investigators

  • Lucio Crino, MD · Bologna Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2007-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234468 on ClinicalTrials.gov